Humane Genomics vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
Synthetic oncolytic virus biotech engineering programmable cancer-killing RNA viruses; $8.12M raised with Union Square Ventures leading 2025 round competing in cancer immunotherapy.
About
Humane Genomics is a synthetic virology biotech company engineering oncolytic viruses — synthetic RNA viruses designed to selectively infect and destroy cancer cells while leaving healthy cells unharmed — using a proprietary platform that programs viral behavior at the genomic level to create next-generation cancer therapies. The company raised $8.12 million in total funding including a February 2025 round led by Union Square Ventures with 14 investor participants, developing RNA-based viral cancer therapies for systemic delivery designed for extended therapeutic activity.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.